Governance Structure of Medical Accessibility

Sino Biopharmaceutical has established a sound governance structure of medical accessibility. The Board is responsible for formulating the Group's healthcare access strategy and objectives, and the Chairman of the Board serves as the board level representative on medical access management issues. As requested by the Board, the Board-Level ESG Committee is responsible for providing guidance and suggestions on the direction of the Group's medical access work, and the Strategic Decision-making Committee is responsible for overseeing the medical access management.

Expanding Therapeutic Areas

Sino Biopharmaceutical and its member companies aim at making good drugs available for more patients to effectively release their pain. To cover the diseases that plague most patients, we target key diseases such as oncology, cardiovascular and cerebrovascular diseases, and continuously increase investment in R&D to constantly launch new products with proven efficacy. In addition to oncology, cardiovascular and cerebrovascular diseases, our products also cover other areas, such as orthopedic disease, liver disease, respiratory system disease, analgesia and parenteral nutrition.

Reducing Patients' Burden

Sino Biopharmaceutical and its member companies adhere to the principle of fair pricing to provide patients with high quality drugs at reasonable prices. Ensuring the drug quality, we strictly control the cost to enhance the competitive edge of drugs in centralized procurement. At the same time, we actively participate in medical insurance negotiation to increase our drug coverage in medical institutions and benefit people with more reasonable prices.

Increasing Distribution Channels

Sino Biopharmaceutical has a nationwide academic marketing network covering most hospitals of secondary level or above in China. In addition to achieving a high domestic market share, the Group actively explores overseas markets to benefit patients worldwide with inexpensive and high-quality products.

R&D of Rare Disease Drugs

Sino Biopharmaceutical follows the guidance of relevant policies such as the Healthy China 2030 Planning Outline and the Guidelines for the Diagnosis and Treatment of Rare Diseases, and makes unremitting effort in rare disease researches and production of rare disease drugs to provide more options to rare disease patients, and guarantee the equal health rights and benefits of patients with rare diseases.

Risk of Antibiotic Resistance

Sino Biopharmaceutical believes that antibiotic resistance has become one of the most pressing public health problems worldwide, remains highly concerned about this issue, and promises to take actions to respond to it. In response to basic research and drug development initiatives for drug-resistant bacteria, the Group continues to increase investment in new drugs and diagnostic technologies, and continues to monitor antibiotic resistance. Combined with industrial advantages, the Group widely spreads the scientific concept of drug use.

Doha Declaration on the TRIPS Agreement and Public Health

Sino Biopharmaceutical explicitly supports the intellectual property model agreed in Doha Declaration on the TRIPS Agreement and Public Health, and recognizes the importance of this model in helping developing countries in need to access medicines under special circumstances. We also see that Doha Declaration on the TRIPS Agreement and Public Health also allows for the import of medicines from countries with strong manufacturing capacity, using compulsory licences, to meet the needs of countries with insufficient manufacturing capacity.